Bioisosterism in Drug Discovery and Development - An Overview

被引:24
|
作者
Jayashree, B. S. [1 ]
Nikhil, P. Sai [1 ]
Paul, Soumyajeet [1 ]
机构
[1] Manipal Acad Higher Educ, Dept Pharmaceut Chem, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India
关键词
Bioisosterism; lead; enzyme inhibition; scaffold hopping; antimetabolites; benzopyrones; carbostyrils; MOLECULAR MODIFICATION; IN-VITRO; AGENTS; ANTICANCER; INHIBITORS; ISOSTERISM; CHALCONES; SCAFFOLD; DESIGN; MOIETY;
D O I
10.2174/1573406418666220127124228
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Bioisosterism is a unique approach used by medicinal chemists for the reasonable modification of lead compounds into safer, more clinically effective, economical, and therapeutically attractive drugs. It is one of the most crucial lead modification tools, widely applied in the field of rational drug design to amplify the desired activity and eliminate undesirable properties, thus facilitating the optimization of pharmacokinetic profile and achievement of target selectivity. This review demonstrates the importance of bioisosterism in the process of drug discovery and development and highlights its relevance in the molecular evolution of many classes of drugs such as antibacterial sulfonamides, anticancer drugs, antivirals, antifungals, anthelmintics, local anesthetics, barbiturates, antidepressants, antihistamines, proton pump inhibitors and work carried out by our team of researchers. The role of bioisosterism as a strategy to achieve inhibition of enzymes such as thymidylate synthase, DNA polymerase, reverse transcriptase and several others has also been pointed out. There are no limits to the classes of drugs where bioisosterism has been successfully applied.
引用
收藏
页码:915 / 925
页数:11
相关论文
共 50 条
  • [41] Antisense drug discovery and development
    Yamamoto, Tsuyoshi
    Nakatani, Moeka
    Narukawa, Keisuke
    Obika, Satoshi
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (03) : 339 - 365
  • [42] Drug Discovery and Development in Academia
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (06) : 1047 - 1047
  • [43] ETHNOBOTANICAL DRUG DISCOVERY AND DEVELOPMENT
    TEMPESTA, MS
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 203 : 100 - AGFD
  • [44] DRUG DEVELOPMENT AND WOMEN - AN OVERVIEW
    GIBALDI, M
    PHARMACOTHERAPY, 1992, 12 (05): : 365 - 368
  • [45] Genetics in drug discovery and development
    Whittaker, John
    JOURNAL OF MEDICAL GENETICS, 2012, 49 : S34 - S34
  • [46] Acceleration of drug discovery and development
    Mehta, Anita A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [47] Deuterium in Drug Discovery and Development
    Harbeson, Scott L.
    Tung, Roger D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 46, 2011, 46 : 403 - 417
  • [48] Integrating drug discovery and development
    Borchardt, RT
    SCIENTIST, 2001, 15 (05): : 43 - 43
  • [49] Adaptivity in Drug Discovery and Development
    Bretz, Frank
    Branson, Michael
    Burman, Carl-Fredrik
    Chuang-Stein, Christy
    Coffey, Christopher S.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (03) : 169 - 190
  • [50] Anticancer drug discovery and development
    Colotta, Francesco
    TARGETED THERAPIES IN CANCER: MYTH OR REALITY?, 2008, 610 : 19 - 42